

FOR IMMEDIATE RELEASE:

**SUPPORT FOR EBI'S RENOPROTECTIVE DRUG PRESENTED
AT ANNUAL ICAAC/IDSA MEETING**

Washington, D.C., October 30, 2008 - During the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ("ICAAC")/Infectious Diseases Society of America ("IDSA") Meeting in Washington, D.C. (October 25-28, 2008) investigators at Cooper University Hospital, Camden, NJ, reported on their studies of EA-230. Led by senior author, R.D. Goldfarb, Ph.D. of the Robert Wood Johnson School of Medicine ("RWJSM"), Camden, NJ, the investigators assessed the effects of EBI's drug on organ function and histology in "a highly fatal peritoneal Gram negative bacteria autologous clot implant into female pigs." Such clots typically lead to severe porcine peritonitis and death.

The experimental protocol was not designed to measure survival but to measure changes in heart, lung, and kidney structure and function. Of the dose regimens tested, the most dramatic results were in the 3-dose group that showed no histological deviations compared with the control groups. In the untreated infected animals the cardiac and renal sections exhibited significant signs of injury.

The investigators examined the urine of the animals for the presence of a particular protein, neutrophil gelatin-associated lipocalin ("NGAL"). An increase of NGAL is thought to be a sign of stimulation of regeneration of renal epithelium. NGAL was elevated in all groups of animals, but most highly in the 3-dose treated group. These findings support the view that EA-230 exerts its effect by improving tissue repair.

Dr. R. Phillip Dellinger, Director of the Division of Critical Care Medicine, of RWJSM commented that "the combination of elevated NGAL and preserved renal histology in the 3 treatment group offers support for renal protection." EBI continues to explore the renoprotective effects of EA-230 in a variety of potential acute clinical settings, including septic shock and cardiovascular surgery.

About Exponential Biotherapies, Inc.

Exponential Biotherapies, Inc ("EBI") is a Virginia based drug discovery and development company with a growing pipeline of novel small molecule drugs to treat a wide range of severe inflammatory disorders such as septic shock, renal failure, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents. The Company's first candidate drug, EA-230, is about to enter Phase II clinical trials following a successful Phase I in which the drug was safely tolerated in both single and multi-dose studies as well as the LPS proof of concept, Phase I Expansion.

The Company has licensed a family of chemically synthesized biomolecules (the "Compounds") that regulate the immune response. These biomolecules can either increase or decrease the

activity of the immune system by affecting the activity of one or more of the components of the immune cascade.

About Cooper Hospital

Cooper University Hospital is the leading provider of comprehensive health services, medical education and clinical research in southern New Jersey and the Delaware Valley. With over 550 physicians in over 75 specialties, Cooper is uniquely equipped to provide an almost unlimited number of medical services. As both the clinical center of The Cooper Health System and the clinical campus of the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School at Camden, the hospital is committed to excellence in medical education, patient care and research.

The hospital is renowned for its prestigious Centers of Excellence in cardiology, cancer, critical care, trauma, orthopedics and neurology. The area's top nurses, doctors and services have earned Cooper the Consumer Choice award three consecutive years by the National Research Corporation. Cooper has embarked on a \$500 million expansion of its Camden Health Care Campus. The new \$220 million Pavilion will open in the fall of 2008. In addition, a new Academic and Research Building for the Robert Wood Johnson Medical School and a new Cancer Center are expected to commence construction within the next year. Cooper also opened its new facilities for the Cooper Digestive Health Institute in Mount Laurel in February, and its expanded outpatient center in Voorhees this September.

Forward-looking statements

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials (including our ability to initiate and complete subsequent clinical trials involving EA-230 or any other product candidate); risks that subsequent clinical trials may show EA-230 is not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of EA-230 or any of our other product candidates; manufacturing issues relating to EA-230 or any other drug candidate; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

Contact

Zsolt Harsanyi, Chairman and CEO

+1-703-883-3701